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We have generated a humanized double-reporter transgenic rat for whole-body in vivo imaging
of endocrine gene expression, using the human prolactin (PRL) gene locus as a physiologically
important endocrine model system. The approach combines the advantages of bacterial artificial
chromosome recombineering to report appropriate regulation of gene expression by distant
elements, with double reporter activity for the study of highly dynamic promoter regulation in
vivo and ex vivo. We show first that this rat transgenic model allows quantitative in vivo imaging
of gene expression in the pituitary gland, allowing the study of pulsatile dynamic activity of the
PRL promoter in normal endocrine cells in different physiological states. Using the dual reporters
in combination, dramatic and unexpected changes in PRL expression were observed after inflamma-
tory challenge. Expression of PRL was shown by RT-PCR to be driven by activation of the alternative
upstream extrapituitary promoter and flow cytometry analysis pointed at diverse immune cells ex-
pressing the reporter gene. These studies demonstrate the effective use of this type of model for
molecular physiology and illustrate the potential for providing novel insight into humangene expres-
sion using a heterologous system. (Molecular Endocrinology 23: 529–538, 2009)
A major challenge in physiology is the understanding andanalysis of dynamic temporal control of gene expression in
living intact tissues in real time in different physiological condi-
tions. In this study we developed transgenic rat lines using large
reporter transgenes in bacterial artificial chromosomes (BACs),
with the purpose of studying dynamic regulation of the impor-
tant hormone prolactin (PRL), assessing gene expression in the
intact animal in vivo and in living cells ex vivo. Surprisingly little
is known about the timing of gene expression in living tissues
and whole organisms, although previous work has indicated
that in cell lines, gene transcription in individual cells behaves in
a highly dynamic and heterogeneous manner (1, 2).
PRL is a polypeptide hormone mainly produced by the lac-
totrope cells of the anterior pituitary gland, and its major func-
tion in mammals is related to lactation (3). The PRL gene is also
expressed in humans and primates at extrapituitary sites, such
as brain, decidualized endometrium, myometrium, and circulat-
ing lymphocytes (4), and more than 300 biological functions
have been attributed to this hormone, including reproduction,
immunomodulation, and behavior. The human PRL gene maps
on the short arm of chromosome 6, and it is organized in five
exons and four introns (4). In human decidua and in lympho-
cytes the PRL mRNA is longer including an extra exon (exon
1a), produced by the activity of an alternative promoter located
5.8 kb upstream of the pituitary transcription start site (4–6). A
number of comparisons suggest that the human and rodent pro-
lactin (Prl) loci are significantly different.Where the human PRL
locus lies in a gene desert (7) surrounded by around one mega-
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base of noncoding DNA (http://genome.ucsc.edu), rodent Prl
genes exist as a large family of 26 closely related paralogous
genes arising from gene duplication (8). The PRL gene families
in the mouse and rat are clustered on chromosomes 13 and 17,
respectively (4). Differential expression of the alternative human
promoter has been suggested to compensate for the lack of ex-
pansion of the PRL gene in primates (9). No mutations have
been described in the human PRL gene, suggesting that such
mutations might be lethal. This differs from studies in mouse
where neither vitality nor immune competency is compromised
in Prl (10) and Prl receptor knockout mice (10, 11), despite
many indications for a role of PRL in the immune system (12).
This is surprising given the high conservation of the PRL gene
sequence in humans. Therefore, the mouse knockout models
available may not be ideal for studying the human PRL gene, as
a result of redundancy of the rodent system.
Here we describe the generation of a humanized double-
transgenic rat that expresses luciferase and destabilized en-
hanced green fluorescent protein (d2eGFP) under the control of
the entire human PRL gene locus. Our strategy is based on a
BAC recombineering approach to permit the inclusion of long-
distance regulatory elements and to minimize site of transgene
integration effects. We have previously used luciferase to image
the dynamic pattern of gene expression, which is characteristic
of the human PRL promoter (2, 13, 14). We show that the
resulting rat double-transgenic model allows in vivo imaging
and ex vivo analysis of human PRL gene expression driven by
the pituitary and also the extrapituitary promoter, making this
an ideal tool for the study of human PRL gene expression in
different physiological and pathological conditions.
Results
Generation of a BAC-reporter transgene
We have generated a BAC-luciferase and a BAC-destabilized
eGFP (d2eGFP) construct by BAC recombineering (15) using
BAC RP11-237G3, which spans 163 kb of the human PRL
genomic locus including 115 kb upstream and 38 kb down-
stream of the PRL gene (Fig. 1A). Both Photinus pyralis lucif-
erase and d2eGFP were selected as reporter genes due to their
short half-life, which allows for the imaging of highly dynamic
gene expression patterns (2) and for their suitability for in vivo
imaging (16, 17).
The BAC was targeted with a linear double-strand DNA
cassette containing either the luciferase or the d2eGFP gene and
a Kan selectable marker flanked by FRT sites. Homologous
recombination arms were designed to span the PRL gene
5-untranslated region (UTR) and the first intron to substitute
exon 1bwith the targeting cassette (Fig. 1) (verified using South-
ern blot hybridization; see supplemental Figs. 1b and 2b pub-
lished as supplemental data on the Endocrine Society’s Journals
Online web site at http://mend.endojournals.org). Exon 1b con-
tains the translation ATG initiator, and its removal prevents the
production of PRL from the targeted transgene.
Hormonal responses of stably transfected BAC cell lines
PRL-Luc BAC construct validation was performed by gener-
ating stably transfected pituitary GH3 cell lines. Eighteen re-
combinant clones were analyzed for basal luciferase activity (see
supplemental Fig. 3), and a subset of nine were challenged with
a variety of well-characterized PRL-regulating stimuli. A com-
parison with GH3 cells expressing luciferase under the control
of 5 kb of human PRL promoter [D44 cell line (2)] is presented
in Fig. 2A. A 2.8-fold induction of luciferase activity was ob-
served in the PRL-Luc BAC cell lines after stimulation with
estrogen compared with the 1.6-fold induction in D44 (P 
0.05) (Ref. 18 and Fig. 2B).
Real-time luminescence imaging showed significantly greater
estrogen induction in the PRL-Luc BAC-transfected GH3 cells
than that observed using the 5-kb PRL promoter (Fig. 2C).
Single cells revealed heterogeneous, fluctuating transcriptional
activity under resting conditions (Fig. 2, D and E), as seen pre-
viously in clonal cell lines (2), adenovirus infected (14), or mi-
croinjected primary pituitary cells (19).
Generation of PRL-Luc and PRL-d2eGFP transgenic rats
The targeted PRL-Luc and PRL-d2eGFP BAC constructs
were injected into the pronucleus of Fisher 344 fertilized rat
oocytes. Of 64 potential founder rats for PRL-Luc construct,
five transgenic rats were identified (PRL-Luc25, PRL-Luc34,
PRL-Luc37, PRL-Luc47, PRL-Luc49), and of 26 potential
founders for PRL-d2eGFP construct, two transgenic rats were
identified by PCR and confirmed by Southern blot hybridization
(data not shown). All the lines except PRL-Luc25 and PRL-
Luc34 transmitted the transgene to their progeny and showed
normal growth and viability. Fluorescence in situ hybridization
(FISH) analysis of interphase and metaphase nuclei showed
multiple insertion sites of the transgene in lines PRL-Luc34,
PRL-Luc37, and PRL-Luc47 (see supplemental Fig. 4), but a
single insertion site in line PRL-Luc49, PRL-d2eGFP455 (Fig.
3A) and PRL-d2eGFP485. Southern blot analysis showed that
more than 155 kb of the transgene was integrated into the
genome of line PRL-Luc 49 in high copy number and in
PRL-d2eGFP455 in low copy number. Thus, these two lines
were selected for further characterization and study. Double
immunocytochemistry analysis shows that a good colocaliza-
tion of PRL/reporter gene signal can be observed in male and
female pituitaries. A higher density of lactotropes was observed
FIG. 1. Diagram showing the BAC targeting strategy using two (luciferase and
d2eGFP) double-strand linear cassettes. 5 Hom, 5-homology arm; Luc,
luciferase; 3Hom, 3-homology arm; Pit, pituitary.
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using immunocytochemistry throughout the female pituitary,
compared with male pituitary (Fig. 3B; P 0.0005) in PRL-Luc
rats. In these animals, expression of luciferase was higher in
females than males (Fig. 3B), and the two genes were coex-
pressed in 93.9%  5.9 of female lactotropes and in 59% 
13.9 of male lactotropes (P  0.0001). In PRL-d2eGFP trans-
genic rats the two genes were coexpressed in 18.4%  8% of
female lactotropes and in 21.6%  8% of male lactotropes
(Fig. 3C).
Endogenous rat Prl and luciferase or d2eGFP gene expres-
sion analysis by quantitative PCR (qPCR) shows a significantly
higher expression of the reporter genes compared with the en-
dogenous Prl (Fig. 3D) in both male and females. In male lucif-
erase transgenic rats, expression of the Prl gene is significantly
decreased, suggesting competition for transcription factors
(transcriptional squelching; Fig. 3D). Human PRL activity was
undetectable by RIA in the transgenic rat plasma and pituitary
homogenates.
In vivo imaging of pituitary-specific expression
In vivo bioluminescence imaging detected strong signals,
1.33  106  6.7  105 p/sec/cm2/steradian (sr) in females and
5.6  105  4.2  105 in males (Fig. 4A), after 30 sec signal
integration time in luciferase transgenic rats lying supine. No
strong signal was detected in this position with the animal lying
prone, most likely due to the optical properties of the brain and
the skull (20). Specificity of the signal for the pituitary glandwas
assessed after the rat was killed (Fig. 4B).
FIG. 2. Analysis of cell lines stably transfected with the PRL-Luc BAC construct. A, Stimulation of BAC cell lines and D44 cells (FOR, 1 M forskolin; TRH 300 nM; FGF-2,
10 ng/ml; Dex 10 nM; and TNF-, 10 ng/ml) for 8 h. Results are shown as fold induction  SD. B, Estrogen (E2) stimulation of BAC cell lines and D44 (1 nM) for 24 h.
Results are shown as fold induction  SD. C, Cell imaging. Estrogen was added at time 0, and images for untreated (upper panels) and treated cells (lower panels) are
shown. Scale bar, 125 m. D, Total photon counts of a whole field of cells (20 cells) with (blue) or without (black) addition of estrogen. E, Quantification of the
transcriptional activity in single cells under resting conditions. The data are the mean intensity of individual cell areas and the mean intensity of the whole field of cells
(20 cells). Dex, Dexamethasone; DMSO, dimethylsulfoxide; FOR, forskolin.
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Ex vivo study of pituitary single-cell gene expression
Pituitaries from transgenic positive animals were harvested
and the cells dispersed. Light emission could be detected in ap-
proximately one third of cells from each dispersed pituitary
gland as assessed by bright-field imaging. Continuous imaging
and photon emission were recorded over 35 h. The cells showed
a dynamic expression pattern, which was not synchronized (Fig.
4C), but similar to the responses in the BAC cell lines (Fig. 2E).
Amovie showing the dynamic and oscillatory pattern of expres-
sion is in supplemental movie 1. Heterogeneity in PRL expres-
sion was also observed in d2eGFP-expressing cells dispersed
from transgenic positive pituitaries (Fig. 4, D and E).
Extrapituitary luciferase expression
PRL expression in man has been demonstrated in a number
of extrapituitary sites including cells of the immune system es-
pecially in T lymphocytes and lymphoid tissues (12). Detectable
levels of luciferase and d2eGFP gene expression and luciferase
activity were found to be present in the thymus and spleen of
transgenic rats, whereas endogenous rat Prl gene expressionwas
absent (see supplemental Fig. 5). Luminescence signals were also
detected in the paws and ears of male and female transgenic rats,
suggesting human PRL promoter-driven luciferase gene expres-
sion in cartilage (Semprini, S., J. R.McNeilly, D. G. Brownstein,
K. Featherstone, L. Ramage, D. M. Salter, J. R. E. Davis, and
J. J. Mullins, manuscript in preparation).
To address possible regulation of PRL promoter activity in
immune-related cells, male rats were injected ip with either
physiological saline (vehicle) or 3 mg/kg of body weight of lipo-
polysaccharide (LPS). After 16 h the rats were anesthetized,
given an ip injection of luciferin, and imaged. One vehicle-
treated and one LPS-treated rat were imaged simultaneously.
Figure 5A shows two representative experiments in which
strong multiple signals were seen in LPS-treated rats in lower
and upper left abdomen, but also overlying the mediastinum
(thymus and parathymic lymph nodes), the axillae (axillary/
brachial lymph nodes), and posterior intermandibular space
(mandibular lymph nodes). This pattern of light emission in
LPS-treated rats suggests luciferase expression in cells resident
in lymphoid tissues, but also in peritoneal exudate cells. Fainter
signals could also be seen in the abdomen of vehicle-injected
rats, and they may be due to local and superficial LPS-indepen-
dent inflammation at the site of ip injection of the vehicle and
luciferin substrate. The vehicle-treated animal in the right panel
FIG. 3. Molecular characterization of BAC PRL-Luc and PRL-d2eGFP transgenic rats. A, FISH analysis of metaphase and interphase nuclei of transgenic rat spleenocytes.
Left panels, PRL-Luciferase line 49; right panel, PRL-d2eGFP line 455. B and C, Fluorescent immunocytochemistry of female (left) and male (right) pituitary sections.
Green fluorescence: luciferase (panel B) or d2eGFP (panel C); red fluorescence indicates PRL. Scale bar, 20 m. D, Real-time qPCR of luciferase, d2eGFP, and rat Prl in
the pituitary gland of female and male transgenic rats. (*, P  0.05 rat Prl vs. luciferase in males and females; n  5 female; n  4 male; *, P  0.05 rat Prl vs. d2eGFP
in males; n  3 female; n  4 male). F, Female; M, male.
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showed very low expression of pituitary luciferase (see supple-
mental Fig. 6).
To assess whether this in vivo expression was reflecting al-
ternative promoter usage in immune-related organs, anRT-PCR
approach was designed to amplify luciferase cDNA in thymus
and spleen of transgenic rats, using two sets of primers. The first
set of primers amplified a portion of cDNA including exon 1a,
the extrapituitary 5-UTR (21), and the pituitary 5-UTR. The
second set of primers amplified a portion of the luciferase gene
as well (Fig. 5B). Amplification was successful in both tissues
with the two sets of primers, demonstrating luciferase expres-
sion driven by the extrapituitary promoter, but a band was
obtained that was 148 bp larger than the expected size and
corresponded to the most abundant amplicon obtained in addi-
tion to the expected fragment (Fig. 5C). Sequence analysis al-
lowed for the precise mapping of the alternative splice acceptor
site to position 246 relative to the luciferase translation start
site (equivalent to the human PRL ATG position). These data
suggest activation of the human alternative PRL promoter upon
immune challenge.
In vivo imaging and ex vivo analysis of PRL-mediated
LPS response in a double-transgenic rat
Double-transgenic PRL-Luc/d2eGFP rats were generated by
mating from single transgenics. Male double-transgenic rats
were injected ipwith either physiological saline (vehicle) or 3mg
LPS/kg of body weight. After 16 h, the rats were anesthetized,
given an ip injection of luciferin, and imaged using the in vivo
imaging system (IVIS) Spectrum. One vehicle-treated and one
LPS-treated rat were imaged simultaneously. Figure 6A shows
bioluminescence imaging of the PRL-mediated immune re-
sponse as was also observed in the PRL-Luc transgenic animals
(Fig. 5A). Furthermore, this model offers the option for fluores-
cence-based analysis of the cellular response to the LPS chal-
lenge. Fluorescent positive cells were observed in the peritoneal
exudate of vehicle and LPS-treated rats in dramatically different
proportions (Fig. 6B) by flow cytometry. Confocal imaging of
peritoneal exudate cells suggested the expression of the d2eGFP
protein by different populations of immune cells, including
monocytes/macrophages and granulocytes (Fig. 6C).
Discussion
We have used a BAC recombineering approach to generate re-
porter transgenic rats that express the luciferase and the d2eGFP
gene under the control of both the pituitary- and extrapituitary-
specific human PRL gene promoters. Whole-body in vivo imag-
ing of human PRL promoter activity in these models readily
reveals physiological pituitary expression and striking evidence
of alternative promoter activation after immune challenge.
The human PRL gene is surrounded by highly conserved
noncoding sequences that span over 1 megabase of genomic
DNA. These sequences are likely to contain functional regula-
tory elements and long-distance enhancers (22, 23). We selected
a BAC clone spanning 163 kb of the human PRL locus and
engineered it to insert either the luciferase or the destabilized
eGFP genes into the human PRL exon 1b, thus removing expres-
sion of human PRL. BAC transgenesis offers several advantages
over the use of small transgenes. These constructs encompass
large stretches of flanking DNA and behave very similarly to the
endogenous gene because effects due to the position of insertion
can be practically nullified (24). They are also readily modified
by BAC recombineering (25) and can be used for generating
transgenic animals and for transfecting mammalian cell lines
(26). To validate the PRL-Luc BAC construct, stably transfected
pituitary GH3-based cell lines were generated. They showed
dramatic heterogeneity in PRL transcription at single-cell level
even under resting conditions, confirming a dynamic pattern of
gene regulation (2, 13, 14, 19).
The BAC cell lines showed a response to a variety of stimuli,
such as forskolin, TRH, fibroblast growth factor 2 (FGF-2), and
TNF-. We have recently demonstrated that TNF- is a stimu-
FIG. 4. In vivo imaging and ex vivo analysis of BAC PRL-Luc and PRL-d2eGFP
transgenic rats. A, In vivo imaging of a female BAC PRL-Luc transgenic rat. The
image was acquired with an IVIS Spectrum (Caliper Life Sciences): 60 sec
integration time, Bin 4, FOV 6.6, f1. B, Image taken after the rat has been
euthanized. C, Ex vivo imaging of single-cell preparations derived from PRL-Luc
transgenic rat pituitary. Left, Bright-field image of the pituitary cells. Middle,
Pseudocolor image of the same cells. Right, Quantification of the dynamic
changes in luminescence from individual cells. Scale bar, 200 m. D, Tile scan
imaging, with a 40 1.3 fluar objective, of a pituitary thick section (400 m)
from PRL-d2eGFP rat. E, Ex vivo imaging of single-cell preparations derived from
PRL-d2eGFP rat pituitary. Left, Bright-field image of the pituitary cells. Middle,
Color image of the same cells. Right, Quantification of the dynamic changes in
fluorescence from individual cells. Scale bar, 200 m.
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lator of the human PRL promoter, and its effect is mediated by
nuclear factor-B signaling pathway (27). Interestingly, the
stimulation of several BAC cell lines with estrogen elicited larger
luciferase emission (18) than D44 cells, which express luciferase
under the control of a shorter human PRL promoter (2). These
data suggest the presence of further estrogen-responsive regula-
FIG. 6. In vivo and ex vivo imaging of reporter genes in LPS-treated PRL-Luc/d2eGFP double-transgenic rats. A, In vivo imaging of vehicle (V) and LPS-treated rats. The rats
were injected i.p either with physiological saline or with 3 mg/ml LPS and imaged 16 h after the treatment. The images were acquired with an IVIS Spectrum (Caliper Life
Sciences): 30 sec integration time, Bin (HR) 8, FOV 19.6, f1. B, Flow cytometric analysis of d2eGFP-positive cells from the peritoneal exudate of a vehicle and a LPS-treated
double-transgenic rat. C, Confocal imaging of cytocentrifuge preparation of cells from the peritoneal exudate of LPS-treated double-transgenic rats. Scale bar, 10 m.
FIG. 5. Extrapituitary expression of luciferase in BAC PRL-Luc transgenic rat. A, In vivo imaging of vehicle (V) and LPS-treated rats. The rats were injected ip (arrows
indicate site of injection) either with physiological saline or with 3 mg/ml LPS and imaged 16 h after the treatment. The images were acquired with an IVIS Spectrum
(Caliper Life Sciences): 30 sec integration time, Bin (HR) 8, FOV 19.6, f1. B, RT-PCR strategy for the analysis of luciferase expression driven by the extrapituitary
promoter. Dotted line, Observed alternative splicing. C, RT-PCR result. M, 100-bp ladder; T, thymus; SP, spleen.
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tory elements in the BAC sequence, in addition to the one iden-
tified at 1189 bp relative to the transcription start site.
Although cell studies are very valuable for looking at molec-
ular mechanisms of gene regulation, in vivo imaging strategies
are very important tools to understand biological processes as
they occur in living animals. We have generated four lines of
BAC PRL-Luc and two lines of BAC PRL-d2eGFP transgenics
but selected luciferase line 49 and eGFP line 455 for further
studies due to the integrity of the BAC construct at a single
insertion point in the rat genome. Immunocytochemistry results
and real-time qPCR taken together show that endogenous rat
Prl and the reporter genes (luciferase and d2eGFP) are expressed
in lactotropes cells at good levels. Given the high transgene copy
number in the PRL-Luc49 line, male transgenic rats showed a
marked reduction in endogenous rat Prl mRNA compared with
the luciferase mRNA. Both pituitaries and plasma of transgenic
rats were tested for production of human PRL, and results were
negative. Having excluded negative feedback by human prolac-
tin on endogenous rat Prl production, one could speculate that
given the sexual dimorphism in the expression of the pituitary-
specific transcription factor Pit-1 (28), transcriptional squelch-
ing could occur in male pituitaries, but to at a lesser extent in
female pituitaries. Indeed, silencing of gene expression has been
reported for large transgenes when present in higher copy num-
bers (eight to 14 copies) (29). The reduced production of endog-
enous rat PRL in male animals could account for the highly
significant reduced number of lactotropes in luciferase trans-
genic male pituitaries. In PRL-d2eGFP animals the low copy
number of the transgene is consistent with a normal expression
of the endogenous rat PRL as shown by the qPCR. A similar, but
low proportion of male and female lactotropes coexpress the
two genes; this could be possibly due to different half-lives of the
proteins, differential expression of the human and rat Prl pro-
moters, or stochastic expression of individual PRL loci under
condition of low stimulation and in different lactotropes sub-
types in the pituitary.
The bioluminescent transgenic rats are valuable tools for
studying gene expression in vivo, because despite the intracra-
nial location of the pituitary gland, high quality images were
obtained with short integration times (30–60 sec) in both males
and females. Although the signal resolution was low when im-
aged through intact tissue (and a precise localization of the light
output could not be determined), the removal of the skull and
the brain revealed pituitary-specific localization of luciferase
expression. Studies on cultured transgenic pituitary cells re-
vealed striking fluctuations in promoter activity, and more de-
tailed ex vivo studies will be important to further characterize
these transcription profiles.
Extrapituitary expression of PRL promoter activity was dra-
matically visualized in BAC transgenic animals when the ani-
mals were challenged with an ip injection of LPS, and we con-
firmed that this arose from alternate promoter usage in vivo.
LPS is themajor virulence factor of Gram-negative bacteria, and
great progress has been made in the elucidation of LPS recogni-
tion and signaling in mammalian cells (30). Recognition of LPS
by macrophages leads to the rapid activation of an intracellular
signaling pathway, which results in the release of proinflamma-
tory mediators and the recruitment of humoral and cellular
components of the immune system. In vivo imaging of male
luciferase transgenic and luciferase/d2eGFP double-transgenic
rats, 16 h after the injection of LPS, showed luciferase signal in
the abdominal area and also in the mediastinum and mandibu-
lar and axillary lymph nodes. The double-transgenic rat poses a
real advantage in the study of the involvement of PRL in the
immune response by combining in vivo imaging with ex vivo
analysis. Flow cytometry analysis has revealed a population of
eGFP-expressing cells in the peritoneal exudate of LPS-treated
rats, which has been confirmed by confocal imaging with the
suggestion that diverse cells types express d2eGFP. These data
suggest that these rat models will therefore allow the in vivo and
ex vivo study of the role of human PRL in immune-related
processes, clarifying its function in autocrine and paracrine im-
munomodulation. Moreover, we have developed a unique ap-
proach for monitoring inflammation processes in vivo in real
time, and this could facilitate the screening of drugs with anti-
inflammatory potential. Despite the recognition of PRL as an
immune cytokine, its synthesis by the immune system is very
low, and resting cells normally require activation to express PRL
(12). Expression of luciferase and d2eGFP was observed by
qPCR in thymus and spleen of unstimulated male and female
transgenic rats, but endogenous rat Prl gene expression was
undetectable. This observation confirms the conflicting evi-
dence regarding PRL gene expression in the rodent immune
system, where it could be both weak and transient. Conversely,
stronger evidence is available for human PRL gene expression in
T lymphocytes and peripheral blood lymphocytes (12) as con-
firmed here by the expression of luciferase in thymus and spleen
of unstimulated rats. We have analyzed gene expression in vivo
and ex vivo in two rat models with independent insertion sites of
the BAC transgene and with different copy numbers and appre-
ciated luciferase activity and fluorescence emission in cells of the
immune system in both models; therefore, these observations
suggest that the transgenic rat models we have generated are
humanized model organisms that could be very valuable for
studying human PRL gene regulation in vivo under physio-
logical and pathological conditions; further studies are now
required to characterize the reporter gene expression in
leukocytes.
Interestingly, the extrapituitary mRNA transcribed in thy-
mus and spleen is 148 bp longer than the previously described
and most common extrapituitary mRNAs (5, 6). However, it is
of note that a less abundant human decidual PRL cDNA has
been reported with the same structure (21).
In conclusion, we have generated humanized reporter-gene
transgenic rats for whole-body imaging and ex vivo study of
human PRL gene expression. These models combine the advan-
tages of BAC recombineering for appropriate regulation of gene
expression and of reporter gene activity for the study of highly
dynamic promoter regulation in vivo and ex vivo in different
tissues. Moreover, it offers the benefit of a heterologous system
for the characterization of human-specific PRL gene expression
in a rat. To our knowledge, these are the first BAC transgenic
rats for in vivo imaging of gene expression. Given the limitations
of the Prl and Prl receptor knockout mouse for the understand-
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ing of human PRL gene function, these transgenic rats provide
the first in vivo model to accurately study the physiological
regulation of the human PRL gene.
Materials and Methods
Transgene construction
BAC RP11-237G3 (CHORI, http://www.chori.org/) was selected.
For the generation of the luciferase recombination cassette, a 5-homol-
ogy arm (234 bp) was amplified using primers 1 and 2 from human BAC
RP11-237G3 and using primers 3 and 4 (see supplemental Table 1
published as supplemental data on The Endocrine Society’s Journals
Online web site at http://mend.endojournals.org) for the 3-homology
arm (227 bp). The homology arms were designed into the human PRL
5-UTR and the first intron, in order to replace the starting ATG of the
human PRL gene (in exon 1b) with the starting codon of the reporter
gene. The FRT-Neo-FRT cassette was PCR amplified from the
pIGCN21 (15) plasmid (kindly provided by Neal Copeland). The PCR
fragments were subcloned into pGL3-promoter plasmid (see supple-
mental Fig. 1a). The luciferase/kanamycin targeting cassette was re-
leased from the pGL3-promoter plasmid by aHindIII/SalI digestion, gel
purified and used for targeting RP11-273G3 BAC by recombineering
(15) in EL250 bacterial strain according to the protocol, available at
http://recombineering.ncifcrf.gov/Protocol.asp. In a second step of re-
combination the kanamycin gene was removed after arabinose induc-
tion of the cells.
Recombinant PRL-Luc BAC clones were screened by Southern blot
hybridization after EcoRI digestion (see supplemental Fig. 1b).
For the generation of the d2eGFP recombination cassette, the pGL3-
promoter plasmid containing the luciferase/kanamycin cassette was tar-
geted with a double-strand linear cassette containing d2eGFP together
with a tetracycline gene flanked by lox-P sites. The luciferase gene was
substituted by the d2eGFP/tetracycline cassette by homologous recom-
bination in EL350 cells (15). In the second step of recombination, the
tetracycline gene was removed after arabinose induction (see supple-
mental Fig. 2).
The new d2eGFP/kanamycin cassette was then released from the
pGL3-promoter plasmid by a HindIII/SalI digestion, gel purified, and
used for targeting RP11-273G3 BAC by recombineering (15) as de-
scribed above.
Cell culture and generation of stable transfected BAC
cell lines
The construction of the GH3/hPRL-luc (D44) cell line was described
previously (2). Cells were maintained in DMEM with pyruvate /glu-
tamax (Life Technologies Inc., Gaithersburg, MD) and 10% fetal calf
serum (Harlan Sera-lab, Belton, UK).
For the generation of the PRL-Luc BAC cell line, GH3 cells (107
cells/ml) were mixed with 30 g of BAC-DNA (after Kanamycin being
substituted by neomycin in the BAC construct) and transfected using an
Easyjet Plus (Equibio (York, UK)) electroporation system (250 V, 600
F). Stable transfectant clones were selected and recloned using G418
(500 g/ml). The clones were screened for luciferase expression and
responses to stimuli (10 nM 17-estradiol; 1 M forskolin; FGF-2, 10
ng/ml; 300 nM TRH; 10 nM dexamethasone; TNF-, 10 ng/ml).
Production of transgenic rats
Recombined RP11-237G3 BAC inserts were freed by a NotI diges-
tion and purified by preparative pulse field gel electrophoresis, -agar-
ase treatment (New England Biolabs, Beverly, MA), and dialysis against
injection buffer (10 mM Tris-HCl, pH 7.5; and 0.1 mM EDTA with 100
mM NaCl) (31). BAC DNA (1 g/ml) was microinjected into the pro-
nucleus of Fisher 344 rats (Harlan Sera-lab) zygotes. Five transgenic
PRL-Luc-positive founders were identified by PCR using primers 5 and
6 (supplemental Table 1) and Southern blot hybridization. Primers 14
and 15 (see supplemental Table 1) were used instead to identify PRL-
d2eGFP-positive founders by PCR. Animal studies were undertaken
under UK Home Office License, following review by local ethics com-
mittee. All rats were housed individually, given free access to water and
standard commercial rat chow (Special Diet Service, Witham Health
Services, Essex, UK), and maintained under controlled conditions of
temperature (21  1 C) and humidity (50  10%), under a 12-h light,
12-h dark cycle. Female rats were treated with 0.04 mg of LHRH
(Sigma-Aldrich) at d 3 to synchronize their estrous cycle before
real-time qPCR.
Cell imaging
Either collagenase type I-dispersed pituitaries or GH3 BAC-trans-
fected cells (105) were cultured in 10% fetal calf serum and then serum
starved for 24 h before imaging. Luciferin (1 mM; BioSynth AG, Staad,
Switzerland) was added at least 10 h before the start of the experiment,
and the cells were transferred to a Zeiss (Welwyn Garden City, Hert-
fordshire, UK) Axiovert 100M in a dark room. The cells were main-
tained at 37 C with 5% CO2–95% air. Bright-field images were taken
before and after luminescence imaging. Luminescence images were ob-
tained using either a Fluar 20, 0.75 NA objective and captured using
a photon-counting charge-coupled device camera (Orca II; Hamamatsu
Photonics, Bridgewater, NJ; Fig. 2) or a Fluar 10, 0.5 numerical ap-
erture objective using a photon-counting Hamamatsu two-stage video
intensification microscope intensified camera (Fig. 4). Sequential im-
ages, each integrated over 30 min, were taken using 4  4 binning and
analyzed using Kinetic Imaging software AQM6 (Andor, Belfast,
Ireland). Regions of interest were drawn around each single cell, and total
photon counts for individual cell areas were obtained from each image.
Mean intensity data were collected after the average instrument
noise (corrected for the number of pixels being used) was subtracted
from the luminescence signal.
FISH
Rat spleen cells were cultured in RPMI 1640 medium/10% fetal calf
serum with LPS (O111:B4, Sigma-Aldrich), 25 g/ml; Concanavalin A
(Sigma-Aldrich), 5 g/ml; and -mercaptoethanol, 0.5%. After 48 h,
colcemid (0.25 g/ml) was added for 60 min. Standard techniques for
hypotonic treatment, methanol/acetic acid fixation, and slide prepara-
tion were used (32).
FISH was performed as previously described (33) using biotin 16-
dUTP (Roche, Indianapolis, IN)-labeled PRL-Luc BAC DNA, a 1:500
dilution of an avidin-fluorescein isothiocyanate (Vector Laboratories)
antibody, followed by 30-min incubation with an antiavidin biotin an-
tibody (1:100) (Vector Laboratories), and a second incubation with the
avidin-fluorescein isothiocyanate antibody. Slides were finally mounted
in Vectashield (Vector Laboratories) containing 4,6-diamidino-2-phe-
nylindole counterstain.
Immunocytochemistry
Immunofluorescent staining was performed as described previously
(34) using the following antibodies: rabbit antiovine PRL (MCNR51)
(35), mouse antiluciferase (P. pyralis) (Invitrogen, Carlsbad, CA/Zymed
Laboratories (South San Francisco, CA) and a monoclonal antibody
against GFP (Aequorea victoria) (CLONTECH) were used at 1:4000
and 1:50 and 1:100, respectively. All tissues were blocked using goat
serum (NGS; Diagnostics Scotland) diluted 1:5 in PBS (pH 7.4) contain-
ing 5% BSA before the addition of the primary antibody. All primary
antibodies were incubated overnight at 4 C. For the direct detection of
PRL in PRL-Luc rats, goat antirabbit Alexa fluor 488 (1:200;Molecular
Probes, Inc., Eugene, OR) was used. However, indirect detection using
biotinylated goat antimouse IgG (1:500; Vector Laboratories) followed
by Streptavidin Alexa 546 (1:200;Molecular Probes) was used to reveal
luciferase. For the detection of PRL in PRL-d2eGFP rats a goat antirab-
bit peroxidase (1:200; DAKO Corp., Carpinteria, CA) was used fol-
lowed by tyramide Cy3 (1:50; PerkinElmer, Wellesley, MA). However,
antigen retrieval and indirect detection with goat antimouse biotinyl-
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ated (1:200; DAKO) followed by avidin Alexa 488 (1:200; Invitrogen)
was performed for detecting eGFP. Finally, sections weremounted using
Permafluor fluorescent mounting medium and then examined using a
Zeiss LSM510 confocal (Zeiss). For each section, four fields were ex-
amined at random, and the number of bihormonal PRL/luciferase and
PRL-only cells were determined using Image-Pro Plus analysis software
(Media Cybernetics, Bethesda, MD) (n  8, total number of fields
counted for each sex).
RT-PCR and qPCR
TotalmRNAwas extracted from rat pituitaries, thymus (parathymic
lymph nodes), and spleen using the TRIzol reagent (Invitrogen). First-
strand cDNA was synthesized using random octamers (8-mers) and
Superscript II (Invitrogen) on 2 g total RNA.
PRL-specific primers and probe were nos. 7, 8, and 9; luciferase-
specific primers and probe were nos. 10, 11, and 12; d2EGFP-specific
primers and probes were nos. 16, 17, and 18 (see supplemental Table 1).
RT-PCR for the detection of extrapituitarymRNAwas performed using
forward primer 98 (6) in PRL exon 1a and reverse primers no. 13 in PRL
5-UTR and no. 11 in the luciferase gene (supplemental Table 1).
Real-time quantitative PCR (qPCR) was performed as described
previously (36) on a LightCycler 480 System (Roche). Each sample was
analyzed in triplicate along with no template controls. The data were
normalized to 18S gene expression.
In vivo studies
Adult male and female rats from line PRL-Luc49 and from double-
transgenics line PRL-Luc/d2EGFP were analyzed. PRL-Luc transgene
expression was monitored in vivo using the approach of biophotonic
imaging (16).
Photons were detected noninvasively using a sensitive IVIS Spectrum
(Caliper Life Sciences, Hopkinton, MA). Rats were anesthetized with
isoflurane and injected with luciferin (Biosynth AG) (150 mg/kg ip in-
jection) 10 min before imaging. Images were taken using the following
parameters: exposure time 30–60 sec, binning 4–8, no filter, f-stop 1,
variable field of view (FOV) 6.6–26. Images were analyzed by using
Living Image Software (Caliper Life Sciences).
Adult PRL-Luc transgenic rats were treated with either 3 mg/kg LPS
O127:B8 (Sigma-Aldrich) or physiological saline by ip injection and
imaged 16 h later.
Flow cytometry analysis
Peritoneal exudate was recovered from double-transgenic rats in
PBS/heparin (5 U/ml) solution. Red blood cells were lysed with a 1 mM
NH4HCO3 and 114 mM NH4Cl solution. The cells were then fixed in
2% formaldehyde in PBS solution and analyzedwith a FACSVantage SE
(Becton Dickinson and Co., Clifton Lakes, NJ) apparatus.
Statistical analysis
Results for real-time PCR are shown as arbitrary units  SD and
for the immunocytochemistry as mean percentage  SD. Statistical
significance for both of these assays was determined by nonparamet-
ric two-tailed Mann-Whitney test. Results were considered signifi-
cant at P  0.05.
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